INREEDI completes tens of millions in Pre-A Series funding to fuel global expansion

Recently, INREEDI announced the completion of a Pre-A Series funding round raising tens of millions of RMB. This round was led by NRL Capital, with the raised funds primarily allocated to accelerate the global market expansion of INREEDI's core product, the BeaShape radiofrequency therapy device, support clinical research for new indications, and advance the development of its follow-up product pipeline.

The BeaShape radiofrequency therapy device incorporates INREEDI's proprietary Continuous Pulse Width Modulation (CPWM) technology and software-defined waveform system. This unique architecture enables precise energy output strategies that replace traditional high-power impulse heating with gentle yet sustained deep tissue heating. By effectively accumulating the required thermal dose for collagen regeneration without relying on cooling systems, the technology ensures both safety and patient comfort during treatment.

Multicenter clinical trial data led by Shanghai Ninth People's Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, has demonstrated exceptional results. Core findings highlighting its significant wrinkle-reduction efficacy and outstanding patient comfort (mean VAS score 0.17) are expected to be formally published in a leading academic journal shortly, providing comprehensive and rigorous scientific validation.

NRL Capital stated: "We maintain a consistent focus on innovative breakthroughs in the medical technology sector. The INREEDI team possesses profound technical expertise and an international R&D vision, complemented by their precise understanding of pain points in the consumer healthcare market—forming the company's core strengths. The outstanding clinical data demonstrated by the BeaShape product—excellent patient comfort alongside remarkable efficacy—has established strong differentiated competitiveness among comparable devices, showcasing its leading position and scarcity value globally. We firmly believe INREEDI has the potential to become a benchmark enterprise in the upgrading wave of domestic innovative consumer medical devices, and even a significant player in the global radiofrequency medical equipment landscape. We remain confident in its ability to create long-term value for the industry."